A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Enlicitide Decanoate; Drug: Lisinopril; Drug: Warfarin

Study type: Interventional

Funder types: Industry

Identifiers

NCT06772779

MK-0616-026 (Other Identifier)

0616-026

Details and patient eligibility

About

The main goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate with warfarin or lisinopril. Researchers want to learn if the amount of warfarin in a person's blood is similar when warfarin is taken alone or with enlicitide decanoate.

Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Warfarin is a drug that reduces risk of blood clotting, and lisinopril is a drug that lowers blood pressure.

Enrollment: 36 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

The key inclusion criteria include but are not limited to:

• Is in good health
• Has a body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m^2

Exclusion criteria

The key exclusion criteria include but are not limited to:

• History of gastrointestinal disease which may affect food or drug absorption, or has had a gastric bypass or similar surgery
• History of cancer

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

36 participants in 2 patient groups

Warfarin Plus Enlicitide Decanoate

Experimental group

Description:

Participants receive oral warfarin and oral enlicitide decanoate.

Treatment:

Drug: Warfarin

Drug: Enlicitide Decanoate

Lisinopril Plus Enlicitide Decanoate

Experimental group

Description:

Participants receive oral lisinopril and oral enlicitide decanoate.

Treatment:

Drug: Lisinopril

Drug: Enlicitide Decanoate